Challenge

MERGE partnered with Kiniksa to launch their first commercial product ARCALYST, a novel IL-1 inhibitor and the first and only treatment for Recurrent Pericarditis (RP). RP is a rare, debilitating autoimmune condition characterized by recurring episodes of pericardial inflammation.

In the 12 months leading to launch, MERGE performed qualitative research with patients and HCPs to understand the RP experience from both a clinical and emotional standpoint.

Outcome

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud.

Results